Ensysce Biosciences, Inc. (ENSC) Revenue History
Annual and quarterly revenue from 2017 to present
ENSC Revenue Over Time (2017–2025)
ENSC Revenue Growth History
2 of 6 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- +122.9%
- FY2021 revenue growth
- -10.2%
- FY2022 revenue growth
- -28.5%
- FY2023 revenue growth
- -11.6%
- FY2024 revenue growth
- +133.5%
- FY2025 revenue growth
- -2.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $961K | -27.2% |
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $493K | -85.6% |
| Q2 2025 | $1.4M | +654.4% |
| Q1 2025 | $1.3M | +331.8% |
| Q4 2024 | $1.3M | +153.1% |
| Q3 2024 | $3.4M | +685.3% |
| Q2 2024 | $182K | -62.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ENSC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ENSC Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 23, 2026, Ensysce Biosciences, Inc. (ENSC) generated trailing twelve-month (TTM) revenue of $2.8 million, reflecting significant decline in growth of -27.2% year-over-year. The most recent quarter (Q1 2026) recorded $960,999 in revenue
Historical Growth Trajectory
ENSC's 5-year compound annual growth rate (CAGR) stands at +5.2%, indicating steady revenue expansion. The 3-year CAGR of +26.2% exceeds the 5-year average, indicating an acceleration in the most recent period. Ensysce Biosciences, Inc.'s highest annual revenue of $5.2 million was recorded in 2024.
Revenue by Segment
ENSC's revenue is primarily driven by MPAR (100%). With over half of revenue concentrated in MPAR, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including COLL (+19.9% YoY), PCRX (+4.6% YoY), and AVDL (+79.9% YoY) — ENSC has underperformed the peer group in revenue growth. Compare ENSC vs COLL →
ENSC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ENSCCurrent | $3M | -27.2% | +5.2% | -202.1% | |
 COLL | $781M | +19.9% | +20.3% | 24.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 AVDL | $169M | +79.9% | +23.4% | -25.1% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
ENSC Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.1M | -2.8% | $0 | - | $-10,240,946 | -202.1% |
| 2024 | $5.2M | +133.5% | $-2,009,405 | -38.6% | $-6,730,000 | -129.2% |
| 2023 | $2.2M | -11.6% | $-5,357,000 | -240.1% | $-10,718,000 | -480.4% |
| 2022 | $2.5M | -28.5% | $-17,312,492 | -686.1% | $-24,222,095 | -959.9% |
| 2021 | $3.5M | -10.2% | $3.5M | 100.0% | $-19,870,431 | -562.7% |
| 2020 | $3.9M | +122.9% | $3.9M | 100.0% | $-1,613,287 | -41.0% |
| 2019 | $1.8M | - | $-1,638,340 | -92.9% | $-8,568,244 | -485.7% |
| 2018 | $0 | - | $-1,559,000 | - | $-959,000 | - |
| 2017 | $0 | - | $0 | - | $-147,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ENSC — Frequently Asked Questions
Quick answers to the most common questions about buying ENSC stock.
Is ENSC's revenue growth accelerating or slowing?
ENSC revenue is declining -27.2% year-over-year. TTM revenue fell to $3M, contrasting with the 5-year CAGR of +5.2%. The reversal reflects either macro headwinds or company-specific challenges.
What is ENSC's revenue history from 2017 to 2026?
Ensysce Biosciences, Inc. (ENSC) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $3M, growing at -27.2% YoY. The 5-year CAGR is +5.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ENSC's long-term revenue growth rate (CAGR)?
Ensysce Biosciences, Inc.'s 5-year revenue CAGR of +5.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -27.2% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ENSC.
Why does ENSC's quarterly revenue fluctuate?
ENSC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Ensysce Biosciences, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is ENSC's revenue distributed by segment?
ENSC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ENSC's revenue compare to industry peers?
Ensysce Biosciences, Inc. (ENSC) with TTM revenue of $3M and -27.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.